Campylobacter Bolton (with Amphotericin)

Hazard statements (CLP)

H317, H334

Code

Statements

H317

May cause an allergic skin reaction

SECTION 2: Hazards identification

According to Regulation (EC) No. 1272/2008 (CLP) Classification of the substance or mixture

Adverse physicochemical, human health and environmental effects

May cause an allergic skin reaction. May cause allergy or asthma symptoms or breathing difficulties if inhaled

Hazard pictograms

GHS08

Signal word

Danger

Contains

Cefoperazone sodium salt; Vancomycin hydrochloride

Hazard statements

H317 - May cause an allergic skin reaction. H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements

P261 - Avoid breathing dust/fume/gas/mist/vapours/spray. P280 - Wear protective gloves/protective clothing/eye protection/face protection/hearing protection. P304+P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing. P321 - Specific treatment (see supplemental first aid instruction on this label). P333+P313 - If skin irritation or rash occurs: Get medical advice/attention. P342+P311 - If experiencing respiratory symptoms: Call a POISON CENTER or doctor.

2.3 Other hazards

Contains no PBT and/or vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII Component Substance(s) not meeting the PBT criteria of REACH Amphotericin B solubilized (1397-89-3) regulation, in accordance with Annex XIII Substance(s) not meeting the vPvB criteria of REACH Amphotericin B solubilized (1397-89-3) regulation, in accordance with Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or substance(s) are not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %

2.1 Classification of the substance or mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP] Respiratory sensitisation, Category 1 H334 Skin sensitisation, Category 1 H317 Full text of H- and EUH-statements: see section 16 Adverse physicochemical, human health and environmental effects May cause an allergic skin reaction. May cause allergy or asthma symptoms or breathing difficulties if inhaled.